Form 4: Certara Executive Reports Stock Transactions

Certara, Inc. reports on stock transactions by Adrian McKemey, President of Drug Development Solutions, involving restricted stock units and tax withholdings.

Summary

• Adrian McKemey, President of Drug Development Solutions at Certara, Inc., reported transactions on April 1, 2026.
• McKemey acquired 10,849 restricted stock units (RSUs) with a transaction code 'M' and a price of $0.
• These RSUs were granted under the Certara, Inc. 2020 Incentive Plan.
• One-third of the RSUs vested and were settled on April 1, 2026.
• The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on April 1, 2027, and April 1, 2028.
• McKemey also disposed of 2,642 shares of common stock with a transaction code 'F' at a price of $5.70, which were withheld to satisfy tax obligations related to RSU vesting.
• Following these transactions, McKemey beneficially owns 8,207 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and vesting schedules, without significant positive or negative financial disclosures.

Positives

• Vesting of restricted stock units indicates continued employee incentive and potential for future value realization.
• The settlement of RSUs and withholding for taxes are standard procedures in executive compensation.
• The remaining RSUs are scheduled to vest over the next two years, suggesting ongoing commitment and potential future equity ownership.

Negatives

• 2,642 shares were disposed of to cover tax withholding obligations, representing a reduction in immediate shareholding.
• The disposal of shares for tax purposes, while standard, reduces the net number of shares retained by the executive.

Risks

• The value of the remaining RSUs is subject to the future stock price performance of Certara, Inc.
• Future vesting dates (April 1, 2027, and April 1, 2028) mean that the executive's full equity stake is contingent on continued employment and company performance.

Future Outlook

The remaining two-thirds of the restricted stock units are scheduled to vest and settle in equal parts on April 1, 2027, and April 1, 2028, indicating a phased release of equity over the next two years.

Industry Context

StockSavvy.ai notes that this Form 4 filing is typical for executives in the life sciences and technology sectors, where equity-based compensation, such as RSUs, is a common tool for aligning executive interests with shareholder value and retaining talent.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and do not immediately indicate a change in the company's outstanding share count beyond normal course tax withholdings.
• Employees: The vesting schedule for RSUs reinforces the company's use of equity as an incentive and retention tool for key personnel.
• Management: Adrian McKemey's equity stake is subject to continued vesting, aligning his financial interests with the company's performance.

Next Steps

• Continued vesting and settlement of remaining RSUs on April 1, 2027, and April 1, 2028.
• Potential future transactions by Adrian McKemey upon vesting of remaining RSUs.

Key Dates

Keywords

Certara Inc, Form 4, Stock Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Adrian McKemey, Tax Withholding, Beneficial Ownership, Securities Exchange Act